1. Home
  2. ORIS vs INDP Comparison

ORIS vs INDP Comparison

Compare ORIS & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORIS
  • INDP
  • Stock Information
  • Founded
  • ORIS 2014
  • INDP 2000
  • Country
  • ORIS China
  • INDP United States
  • Employees
  • ORIS N/A
  • INDP N/A
  • Industry
  • ORIS Farming/Seeds/Milling
  • INDP Biotechnology: Pharmaceutical Preparations
  • Sector
  • ORIS Consumer Staples
  • INDP Health Care
  • Exchange
  • ORIS Nasdaq
  • INDP Nasdaq
  • Market Cap
  • ORIS 5.3M
  • INDP 6.0M
  • IPO Year
  • ORIS 2024
  • INDP N/A
  • Fundamental
  • Price
  • ORIS $0.16
  • INDP $3.47
  • Analyst Decision
  • ORIS
  • INDP Strong Buy
  • Analyst Count
  • ORIS 0
  • INDP 2
  • Target Price
  • ORIS N/A
  • INDP $238.00
  • AVG Volume (30 Days)
  • ORIS 37.8M
  • INDP 1.4M
  • Earning Date
  • ORIS 01-01-0001
  • INDP 11-11-2025
  • Dividend Yield
  • ORIS N/A
  • INDP N/A
  • EPS Growth
  • ORIS N/A
  • INDP N/A
  • EPS
  • ORIS 0.17
  • INDP N/A
  • Revenue
  • ORIS $15,014,000.00
  • INDP N/A
  • Revenue This Year
  • ORIS N/A
  • INDP N/A
  • Revenue Next Year
  • ORIS N/A
  • INDP N/A
  • P/E Ratio
  • ORIS $0.98
  • INDP N/A
  • Revenue Growth
  • ORIS N/A
  • INDP N/A
  • 52 Week Low
  • ORIS $0.08
  • INDP $2.22
  • 52 Week High
  • ORIS $56.01
  • INDP $58.24
  • Technical
  • Relative Strength Index (RSI)
  • ORIS 45.64
  • INDP 44.80
  • Support Level
  • ORIS $0.14
  • INDP $3.74
  • Resistance Level
  • ORIS $0.17
  • INDP $5.25
  • Average True Range (ATR)
  • ORIS 0.03
  • INDP 0.81
  • MACD
  • ORIS -0.00
  • INDP 0.15
  • Stochastic Oscillator
  • ORIS 10.19
  • INDP 26.24

About ORIS Oriental Rise Holdings Limited Ordinary Shares

Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: